{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-012158","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.600784+00:00","generated_at":"2026-05-15T08:05:49.687703+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Galectin Therapeutics reports FY2025 net loss $31M; belapectin data for EASL upcoming","bullets":["Net loss $31.0M ($0.48/share) vs $47.2M ($0.76) in 2024; R&D expense down to $14.3M from $36.6M.","Cash $17.7M plus $10M credit line from chairman; runway through April 2027.","Belapectin NAVIGATE trial: varices incidence reduced 49.3% in per-protocol (p=0.04); U.S. subgroup 68.1% (p=0.02).","Additional biomarker data (FibroScan, ELF, PRO-C3) support antifibrotic activity; oral/poster presentations at EASL 2026.","Upcoming FDA meeting in Q2 2026 to align on next steps; no approved therapy for MASH cirrhosis."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-012158","json":"https://secwatch.observer/filing/0001140361-26-012158.json","markdown":"https://secwatch.observer/filing/0001140361-26-012158.md","text":"https://secwatch.observer/filing/0001140361-26-012158.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036126012158/0001140361-26-012158-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036126012158/ef20068722_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:05:49.687703+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"efb33c41d245b75073df697bb69f1c66a47bf4db","claim":"GALECTIN THERAPEUTICS INC reported financial results for the year ended December 31, 2025.","evidence_excerpt":"Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133416/000114036126012158/0001140361-26-012158-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}